Insight

Yüksel Ürün: Top Advances of the Year in Perioperative Therapy for Lung Cancer

Photo from Yüksel Ürün/X

May 18, 2024, 10:20

Yüksel Ürün: Top Advances of the Year in Perioperative Therapy for Lung Cancer

Yüksel Ürün shared on X: .

“Top Advances of the Year: Perioperative Therapy for Lung Cancer

In 2023, perioperative immune checkpoint inhibitors (ICIs) became a game-changer for early-stage non-small cell lung cancer (NSCLC)
Despite these advances, optimizing patient selection and biomarker use remains a challenge”

Read further.
Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes.

His dedication to patient care and research inspires positive change in the medical field.

Ankara University School of Medicine cancer Immune checkpoint inhibitors (ICIs) Lung cancer non small cell lung cancer NSCLC OncoDaily Oncology Perioperative Therapy Top Advances of the Year Yüksel Ürün

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage